Radioisotope Production (Iodine-131)

I-131 decays by beta emission and gamma emission with a half-life of 8.02 days. It is typically produced in nuclear reactors by neutron irradiation of tellurium. The resulting I-131 is then chemically separated and incorporated into radiopharmaceuticals. Supply chain considerations involve the availability of nuclear reactors, tellurium targets, and radiochemistry facilities. Logistical challenges include the transport and handling of radioactive materials. Accessibility for developing countries is limited by the specialised facilities and regulatory requirements.

I-131 production and application are well-established, with widespread use in nuclear medicine.

I-131 is a radioactive isotope that emits beta and gamma radiation, requiring careful handling and shielding to minimise radiation exposure.

While I-131 is not a proliferation concern, proper control and monitoring are necessary to prevent unauthorised access or misuse.

Traditional IAEA safeguards are not directly applicable due to the absence of fissile materials. However, monitoring and verification of the production and use of I-131 may be considered to ensure transparency and prevent misuse.